Long-Term Liabilities: The sum of all non-current liabilities.
Quince Therapeutics, Inc. (QNCX) had Long-Term Liabilities of $2.18M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$35.91M |
|
-- |
|
-- |
|
$14.59M |
|
$-14.59M |
|
$45.16M |
|
$30.57M |
|
$30.57M |
|
$35.91M |
|
$35.91M |
|
$35.91M |
|
$35.91M |
|
$-14.59M |
|
$-14.62M |
|
9.12M |
|
9.19M |
|
$3.60 |
|
$2.88 |
|
| Balance Sheet Financials | |
$25.58M |
|
$0.55M |
|
$1.04M |
|
$26.62M |
|
$8.77M |
|
-- |
|
|
Long-Term Liabilities |
$2.18M |
$10.95M |
|
$15.67M |
|
$15.67M |
|
$15.67M |
|
13.79M |
|
| Cash Flow Statement Financials | |
$-7.63M |
|
$12.00M |
|
$9.44M |
|
$5.81M |
|
$18.16M |
|
$12.35M |
|
$1.29M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.92 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.63M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
229.15% |
|
229.15% |
|
134.89% |
|
229.15% |
|
$1.14 |
|
$-0.83 |
|
$-0.83 |
|